CL2008001517A1 - Dispositivo para determinar el riesgo de progresion de melanoma que comprende oligonucleotidos de uno o mas marcadores de pronostico de melanoma (mpms) escogidos de un grupo de seleccion; procedimiento para determinar la prognosis de melanoma en un paciente; procedimiento para determinar la adecuacion de un paciente de melanoma para un ensayo de droga. - Google Patents
Dispositivo para determinar el riesgo de progresion de melanoma que comprende oligonucleotidos de uno o mas marcadores de pronostico de melanoma (mpms) escogidos de un grupo de seleccion; procedimiento para determinar la prognosis de melanoma en un paciente; procedimiento para determinar la adecuacion de un paciente de melanoma para un ensayo de droga.Info
- Publication number
- CL2008001517A1 CL2008001517A1 CL2008001517A CL2008001517A CL2008001517A1 CL 2008001517 A1 CL2008001517 A1 CL 2008001517A1 CL 2008001517 A CL2008001517 A CL 2008001517A CL 2008001517 A CL2008001517 A CL 2008001517A CL 2008001517 A1 CL2008001517 A1 CL 2008001517A1
- Authority
- CL
- Chile
- Prior art keywords
- melanoma
- determining
- patient
- procedure
- prognosis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Medical Informatics (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Databases & Information Systems (AREA)
- Data Mining & Analysis (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Peptides Or Proteins (AREA)
Abstract
MARCADORES DE PRONÓSTICO, PRONÓSTICO IDENTIFICADOR Y COMPOSICIONES Y PROCEDIMIENTOS PARA DETERMINAR LA PROGNOSIS DE CÁNCER EN UN PACIENTE, PARTICULARMENTE PARA MELANOMA. ESPECÍFICAMENTE, LA INVENCIÓN SE REFIERE AL USO DE MARCADORES GENÉTICOS Y DE PROTEÍNA PARA LA PREDICCIÓN DEL RIESGO DE PROGRESIÓN DE UN CÁNCER, TAL COMO MELANOMA, BASADO EN MARCADORES Y FIRMAS DE MARCADORES. EN VARIOS ASPECTOS, LA INVENCIÓN PROVEE PROCEDIMIENTOS, COMPOSICIONES, JUEGOS Y DISPOSITIVOS BASADOS EN MARCADORES DE PRONÓSTICO DE CÁNCER, ESPECÍFICAMENTE MARCADORES DE PRONÓSTICO DE MELANOMA, PARA AYUDAR EN LA PROGNOSIS Y TRATAMIENTO DEL CÁNCER.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ555363A NZ555363A (en) | 2007-05-24 | 2007-05-24 | Prognosis prediction for melanoma cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2008001517A1 true CL2008001517A1 (es) | 2009-01-09 |
Family
ID=40032133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2008001517A CL2008001517A1 (es) | 2007-05-24 | 2008-05-23 | Dispositivo para determinar el riesgo de progresion de melanoma que comprende oligonucleotidos de uno o mas marcadores de pronostico de melanoma (mpms) escogidos de un grupo de seleccion; procedimiento para determinar la prognosis de melanoma en un paciente; procedimiento para determinar la adecuacion de un paciente de melanoma para un ensayo de droga. |
Country Status (17)
Country | Link |
---|---|
US (3) | US8822149B2 (es) |
EP (2) | EP2158332B1 (es) |
JP (5) | JP5943315B2 (es) |
CN (1) | CN101743327B (es) |
AR (1) | AR066725A1 (es) |
AU (1) | AU2008253836B2 (es) |
CA (1) | CA2725602A1 (es) |
CL (1) | CL2008001517A1 (es) |
DK (2) | DK3176270T3 (es) |
ES (2) | ES2821300T3 (es) |
HK (1) | HK1145342A1 (es) |
NZ (1) | NZ555363A (es) |
PT (2) | PT3176270T (es) |
SG (2) | SG10201509568QA (es) |
TW (2) | TWI609967B (es) |
UY (1) | UY31105A1 (es) |
WO (1) | WO2008143533A1 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120135415A1 (en) * | 2002-11-15 | 2012-05-31 | Morehouse School Of Medicine | Detecting cancer with anti-cxcl13 and anti-cxcr5 antibodies |
PL2140269T3 (pl) | 2007-03-27 | 2014-07-31 | Immunovia Ab | Podpis białkowy/znaczniki do wykrywania gruczolakoraka |
JP5683280B2 (ja) * | 2011-01-04 | 2015-03-11 | 株式会社日立製作所 | 診療支援システム |
CN102617734B (zh) * | 2011-12-28 | 2013-09-04 | 暨南大学 | 抗FGF-2抗体Dab-2及其应用 |
US9336302B1 (en) | 2012-07-20 | 2016-05-10 | Zuci Realty Llc | Insight and algorithmic clustering for automated synthesis |
US9355105B2 (en) * | 2012-12-19 | 2016-05-31 | International Business Machines Corporation | Indexing of large scale patient set |
ES2947946T3 (es) | 2013-03-14 | 2023-08-24 | Castle Biosciences Inc | Métodos para predecir el riesgo de metástasis en melanoma cutáneo |
US10687711B2 (en) * | 2015-05-05 | 2020-06-23 | Medizinische Universität Wien | Computerized device and method for processing image data |
WO2018009887A1 (en) * | 2016-07-08 | 2018-01-11 | University Of Hawaii | Joint analysis of multiple high-dimensional data using sparse matrix approximations of rank-1 |
US11205103B2 (en) | 2016-12-09 | 2021-12-21 | The Research Foundation for the State University | Semisupervised autoencoder for sentiment analysis |
US10692605B2 (en) | 2018-01-08 | 2020-06-23 | International Business Machines Corporation | Library screening for cancer probability |
TW202018727A (zh) | 2018-11-09 | 2020-05-16 | 財團法人工業技術研究院 | 整體式學習預測方法與系統 |
US11216742B2 (en) | 2019-03-04 | 2022-01-04 | Iocurrents, Inc. | Data compression and communication using machine learning |
GB202010970D0 (en) | 2020-07-16 | 2020-09-02 | Immunovia Ab | Methods, arrays and uses thereof |
CN112200391B (zh) * | 2020-11-17 | 2023-07-04 | 国网陕西省电力公司经济技术研究院 | 基于k-近邻互信息特征简化的配电网边缘侧负荷预测方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1846362A2 (en) | 2005-01-05 | 2007-10-24 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
AU2006203830A1 (en) * | 2005-01-07 | 2006-07-13 | The Johins Hopkins University | Biomarkers for melanoma |
US7615349B2 (en) * | 2006-09-07 | 2009-11-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Melanoma gene signature |
WO2008043018A1 (en) * | 2006-10-04 | 2008-04-10 | Dana-Farber Cancer Institute, Inc. | Tumor immunity |
-
2007
- 2007-05-24 NZ NZ555363A patent/NZ555363A/en unknown
-
2008
- 2008-05-23 TW TW103127682A patent/TWI609967B/zh not_active IP Right Cessation
- 2008-05-23 ES ES16203301T patent/ES2821300T3/es active Active
- 2008-05-23 CN CN2008800248635A patent/CN101743327B/zh not_active Expired - Fee Related
- 2008-05-23 SG SG10201509568QA patent/SG10201509568QA/en unknown
- 2008-05-23 DK DK16203301.3T patent/DK3176270T3/da active
- 2008-05-23 SG SG10201912289SA patent/SG10201912289SA/en unknown
- 2008-05-23 CL CL2008001517A patent/CL2008001517A1/es unknown
- 2008-05-23 PT PT162033013T patent/PT3176270T/pt unknown
- 2008-05-23 EP EP08766967.7A patent/EP2158332B1/en active Active
- 2008-05-23 TW TW097119301A patent/TWI582236B/zh not_active IP Right Cessation
- 2008-05-23 DK DK08766967.7T patent/DK2158332T3/en active
- 2008-05-23 WO PCT/NZ2008/000118 patent/WO2008143533A1/en active Application Filing
- 2008-05-23 ES ES08766967.7T patent/ES2622858T3/es active Active
- 2008-05-23 EP EP16203301.3A patent/EP3176270B1/en active Active
- 2008-05-23 AU AU2008253836A patent/AU2008253836B2/en not_active Ceased
- 2008-05-23 CA CA2725602A patent/CA2725602A1/en not_active Abandoned
- 2008-05-23 JP JP2010509293A patent/JP5943315B2/ja not_active Expired - Fee Related
- 2008-05-23 PT PT87669677T patent/PT2158332T/pt unknown
- 2008-05-26 AR ARP080102210A patent/AR066725A1/es active IP Right Grant
- 2008-05-26 UY UY31105A patent/UY31105A1/es active IP Right Grant
-
2009
- 2009-11-23 US US12/592,385 patent/US8822149B2/en active Active
-
2010
- 2010-12-16 HK HK10111778.3A patent/HK1145342A1/xx not_active IP Right Cessation
-
2014
- 2014-08-29 US US14/472,755 patent/US9534258B2/en active Active
- 2014-10-31 JP JP2014223331A patent/JP2015061528A/ja active Pending
-
2016
- 2016-12-14 JP JP2016242254A patent/JP6404304B2/ja not_active Expired - Fee Related
- 2016-12-27 US US15/391,293 patent/US10266902B2/en not_active Expired - Fee Related
-
2018
- 2018-09-12 JP JP2018170779A patent/JP2019004907A/ja active Pending
-
2020
- 2020-06-04 JP JP2020097666A patent/JP2020150949A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2008001517A1 (es) | Dispositivo para determinar el riesgo de progresion de melanoma que comprende oligonucleotidos de uno o mas marcadores de pronostico de melanoma (mpms) escogidos de un grupo de seleccion; procedimiento para determinar la prognosis de melanoma en un paciente; procedimiento para determinar la adecuacion de un paciente de melanoma para un ensayo de droga. | |
WO2012006589A3 (en) | Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling | |
EA200970891A1 (ru) | Генетические варианты chr2 и chr16 в качестве маркеров для применения при оценке риска, диагностировании, прогнозировании и лечении рака молочной железы | |
HK1215249A1 (zh) | 標記的前列腺特異性膜抗原 的抑制子、生物學評估及作為成像試劑的用途 | |
ATE449097T1 (de) | Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer | |
EA201170252A1 (ru) | Амидофеноксиндазолы в качестве ингибиторов c-мет | |
EA200971131A1 (ru) | Биомаркеры для прогнозирования чувствительности или отсутствия чувствительности к анти-фно агентам | |
EA201201036A1 (ru) | Целевые геномные изменения | |
CL2007003649A1 (es) | Un conjugado de molecula asociado a anticuerpo monoclonal humano anti-cd70; composicion que comprende al conjugado de molecula asociado a anticuerpo; metodo de inhibicion del crecimiento de celulas tumorales que expresan cd70. | |
MX2009012625A (es) | Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21. | |
MX346450B (es) | Composiciones y métodos para el tratamiento de la enfermedad celíaca. | |
ATE536371T1 (de) | Verfahren und zusammensetzungen zur gendeaktivierung | |
CL2010001483A1 (es) | Compuestos derivados de 5-fenil-1h-piridin-2-ona y 6-fenil-2h-piridazin-3-ona, inhibidores de tirosina-quinasa (btk); composicion farmaceutica que comprende a dichos compuestos y su uso para el tratamiento de un estado patologico inflamatorio y/o autoinmune. | |
WO2007030611A3 (en) | A calculated index of genomic expression of estrogen receptor (er) and er related genes | |
MX2015005448A (es) | Metodos de terapia y diagnostico relacionados con lisil oxidasa-tipo 2 (loxl2). | |
MA34057B1 (fr) | Compositions et methodes pour le diagnostic et le traitement d'une tumeur | |
EA200971068A1 (ru) | Триазолиламинопиримидиновые соединения | |
BR112014032728A2 (pt) | uso de marcadores no diagnóstico e tratamento de câncer de próstata | |
WO2007146668A3 (en) | Use of imp3 as a prognostic marker for cancer | |
WO2015073896A3 (en) | Biomarkers for psma targeted therapy for prostate cancer | |
BR112012033280A2 (pt) | sistema e método comunicação, programa, e, meio de armazenamento da informação | |
CL2007002388A1 (es) | Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas. | |
WO2008028963A3 (en) | Calreticulin for its use as a medication for the treatment of cancer in a mammal | |
MX2010001571A (es) | Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico. | |
AR097909A1 (es) | Método para determinar el pronóstico del cáncer de páncreas |